Association of Androgen Receptor, Prostate-Specific Antigen, and CYP19 Gene Polymorphisms with Prostate Carcinoma and Benign Prostatic Hyperplasia in a North Indian Population

被引:13
|
作者
Soni, Abha [1 ]
Bansal, Anju [1 ]
Mishra, Ashwani Kumar [1 ]
Batra, Jyotsna [2 ,3 ]
Singh, Laishram Chandreshwor [1 ]
Chakraborty, Anurupa [1 ]
Yadav, Dhirendra Singh [1 ]
Mohanty, Nayan K. [4 ,5 ]
Saxena, Sunita [1 ]
机构
[1] Natl Inst Pathol ICMR, New Delhi 110029, India
[2] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4001, Australia
[3] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia
[4] Safdarjang Hosp, Dept Urol, New Delhi, India
[5] Vardhman Mahavir Med Coll, New Delhi, India
基金
澳大利亚国家健康与医学研究理事会;
关键词
CAG REPEAT LENGTH; CANCER; RISK; AROMATASE; PSA; IDENTIFICATION; EXPRESSION; IMPACT; GGN;
D O I
10.1089/gtmb.2011.0322
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The genes involved in androgen pathway and metabolism have been reported to contribute considerably to prostate carcinoma (CaP) risk. The present study investigated the association of androgen receptor (AR), prostate-specific antigen (PSA or KLK3), and cytochrome P450 (CYP19) gene polymorphisms in CaP (n = 105) and benign prostatic hyperplasia (BPH) (n = 120) in comparison to normal healthy controls (n = 106) in an Indian population. We also evaluated the functional consequences of these gene variants on AR and PSA mRNA expression. Significant association of short AR CAG repeats (<= 24) with risk of CaP (odds ratios [OR] = 2.98, p < 0.001) and BPH (OR = 1.96, p = 0.01) was observed; however, CYP19 gene polymorphism was not found to be associated with disease phenotype (p > 0.05). PSA G-158A SNP was found to be significantly associated with risk of CaP (AA: OR = 2.68, p = 0.016 and GA: OR = 2.07, p = 0.018) p-trend 0.031 and BPH (AA: OR = 3.46, p < 0.001 and GA: OR = 2.47, p = 0.03) p-trend 0.009, respectively. PSA G-158A genotype independently increased the risk of developing BPH (OR = 16.37, p < 0.001), irrespective of AR CAG repeat length. Using quantitative real-time polymerase chain reaction, we found a significant upregulation of AR and PSA mRNA expression in CaP comparison to BPH. While short AR CAG (<= 24) repeats were associated with higher AR mRNA expression in CaP (p = 0.002), the PSA SNP did not correlate with its mRNA expression. Interestingly, significantly higher risk estimates for CaP were observed for the combined analysis of short AR CAG and CYP19 genotypes (A2A2) (OR = 7.18, p < 0.001) or A2A3 (OR = 7.60, p = 0.004). Our results suggest significant association of androgen signaling gene polymorphisms with risk of CaP and BPH and provide evidence for a putative functional role of AR CAG repeat in regulating its mRNA expression and warrant the need of larger studies in the Indian population to confirm our results.
引用
收藏
页码:835 / 840
页数:6
相关论文
共 50 条
  • [41] Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen
    Modi P.
    Helfand B.T.
    McVary K.T.
    Current Urology Reports, 2010, 11 (4) : 224 - 227
  • [42] Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia
    Bartsch, G
    Fitzpatrick, JM
    Schalken, JA
    Isaacs, J
    Nordling, J
    Roehrborn, CG
    BJU INTERNATIONAL, 2004, 93 : 27 - 29
  • [43] INFLUENCE OF BENIGN PROSTATIC HYPERPLASIA, TESTOSTERONE AND AGE ON SERUM LEVELS OF PROSTATE-SPECIFIC ANTIGEN
    AUS, G
    BERGDAHL, S
    HUGOSSON, J
    LODDING, P
    NORLEN, L
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1994, 28 (04): : 379 - 384
  • [44] EFFECT OF INFLAMMATION AND BENIGN PROSTATIC HYPERPLASIA ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS
    NADLER, RB
    HUMPHREY, PA
    SMITH, DS
    CATALONA, WJ
    RATLIFF, TL
    JOURNAL OF UROLOGY, 1995, 154 (02): : 407 - 413
  • [45] High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia
    Meigs, JB
    Barry, MJ
    Giovannucci, E
    Rimm, EB
    Stampfer, MJ
    Kawachi, I
    AMERICAN JOURNAL OF MEDICINE, 1998, 104 (06): : 517 - 525
  • [46] Prostate-specific antigen, androgen, progesterone and oestrogen receptors in Benign prostatic hyperplasia: human tissues and animal model study
    Wang, Haohan
    Liu, Chengcheng
    Dong, Ziqiang
    Chen, Xiaobo
    Zhang, Ping
    AGING MALE, 2024, 27 (01):
  • [47] A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus α1-antichymotrypsin-prostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia
    Jung, K
    Brux, B
    Knäbich, A
    Lein, M
    Sinha, P
    Schnorr, D
    Loening, SA
    CLINICAL CHEMISTRY, 1999, 45 (03) : 422 - 424
  • [48] Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia
    Lee, Sang Eun
    Chung, Jae Seung
    Han, Byung Kyu
    Moon, Ki Hyuk
    Hwang, Sung Il
    Lee, Hak Jong
    Choe, Gheeyoung
    Hong, Sung Kyu
    UROLOGY, 2008, 71 (03) : 395 - 398
  • [49] Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia
    Gunes, Sezgin
    Bagci, Hasan
    Sarikaya, Saban
    Bilen, Cenk Yucel
    Kara, Nurten
    DNA AND CELL BIOLOGY, 2007, 26 (12) : 873 - 878
  • [50] Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer
    Das, Kakoli
    Cheah, Peh Yean
    Lim, Pei Li
    Zain, Yasmin Bte Mohad
    Fook-Chong, Stephanie
    Zhao, Yi
    Cheng, Christopher
    Lau, Weber
    CANCER LETTERS, 2008, 268 (02) : 340 - 347